Health insurers are likely to cover the Covid-19 treatment drug remdesivir, but prices paid by patients will vary based on their coverage.
The drug, the first approved by the Food and Drug Administration to treat the coronavirus, is given to patients in hospitals to help them recover more quickly. Representatives for both UnitedHealthcare and Anthem said Friday that the leading insurers are covering remdesivir and are waiving—at least for the time being—cost-sharing such as copays and deductibles.
Out-of-pocket costs are always a major issue with health insurance, and Gilead Sciences Inc.'s $3,120 price to hospitals has drawn criticism ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.